PDF(Pubmed)
Abstract：
BACKGROUND: Advancements in cancer treatments have successfully improved central nervous system (CNS) cancer survivorship and overall quality of life. As a result, the awareness of the importance of fertility preservation techniques is increasing. Currently, a range of established techniques, such as oocyte cryopreservation and sperm cryopreservation, are available. However, oncologists may be hesitant to refer patients to a reproductive specialist.
OBJECTIVE: The primary aim of the proposed systematic review is to assess the best evidence for fertility preservation techniques used in patients with CNS cancers. It also aims to evaluate outcomes related to their success and complications.
METHODS: This protocol was produced in adherence with the PRISMA-P (Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols). Electronic databases will be systematically searched to identify studies that meet our eligibility criteria. Studies will be included if they report at least one type of fertility preserving or sparing technique in male patients of any age and female patients aged <35 years. Animal studies, non-English studies, editorials, and guidelines will be excluded from the review. From the included studies, data will be extracted and synthesized by using a narrative approach and summarized in tables. The primary outcome will be the number of patients successfully undergoing a fertility preservation technique. The secondary outcomes will include the number of retrieved oocytes, the number of oocytes or embryos vitrified for cryopreservation, clinical pregnancy, and live birth. The quality of the included studies will be assessed by using the National Heart, Lung, and Blood Institute risk-of-bias tool for any type of study.
RESULTS: The systematic review is expected to be completed by the end of 2023, and results will be published in a peer-reviewed journal and on PROSPERO.
CONCLUSIONS: The proposed systematic review will summarize the fertility preservation techniques available for patients with CNS cancers. Given the improvement in cancer survivorship, it is becoming increasingly important to educate patients about fertility preservation techniques. There are likely to be several limitations to this systematic review. Current literature is likely to be of low quality due to insufficient numbers, and there may be difficulty in accessing data sets. However, it is our hope that the results from the systematic review provide an evidence base to help inform the referral of patients with CNS cancers for fertility preservation treatments.
BACKGROUND: PROSPERO CRD42022352810; https://tinyurl.com/69xd9add.
UNASSIGNED: PRR1-10.2196/44825.
OBJECTIVE: The primary aim of the proposed systematic review is to assess the best evidence for fertility preservation techniques used in patients with CNS cancers. It also aims to evaluate outcomes related to their success and complications.
METHODS: This protocol was produced in adherence with the PRISMA-P (Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols). Electronic databases will be systematically searched to identify studies that meet our eligibility criteria. Studies will be included if they report at least one type of fertility preserving or sparing technique in male patients of any age and female patients aged <35 years. Animal studies, non-English studies, editorials, and guidelines will be excluded from the review. From the included studies, data will be extracted and synthesized by using a narrative approach and summarized in tables. The primary outcome will be the number of patients successfully undergoing a fertility preservation technique. The secondary outcomes will include the number of retrieved oocytes, the number of oocytes or embryos vitrified for cryopreservation, clinical pregnancy, and live birth. The quality of the included studies will be assessed by using the National Heart, Lung, and Blood Institute risk-of-bias tool for any type of study.
RESULTS: The systematic review is expected to be completed by the end of 2023, and results will be published in a peer-reviewed journal and on PROSPERO.
CONCLUSIONS: The proposed systematic review will summarize the fertility preservation techniques available for patients with CNS cancers. Given the improvement in cancer survivorship, it is becoming increasingly important to educate patients about fertility preservation techniques. There are likely to be several limitations to this systematic review. Current literature is likely to be of low quality due to insufficient numbers, and there may be difficulty in accessing data sets. However, it is our hope that the results from the systematic review provide an evidence base to help inform the referral of patients with CNS cancers for fertility preservation treatments.
BACKGROUND: PROSPERO CRD42022352810; https://tinyurl.com/69xd9add.
UNASSIGNED: PRR1-10.2196/44825.
摘要：
背景：癌症治疗的进步已经成功地改善了中枢神经系统（CNS）癌症的生存率和整体生活质量。因此,对生育保存技术重要性的认识日益提高。目前,一系列既定的技术，例如卵母细胞冷冻保存和精子冷冻保存，是可用的。然而,肿瘤学家可能会犹豫是否将患者转诊给生殖专家。
目的：拟议的系统评价的主要目的是评估中枢神经系统癌症患者使用生育力保护技术的最佳证据。它还旨在评估与成功和并发症相关的结果。
方法：本方案遵循PRISMA-P（系统评价和Meta分析方案的首选报告项目）。将系统地搜索电子数据库，以确定符合我们资格标准的研究。如果他们报告任何年龄的男性患者和年龄<35岁的女性患者中至少一种类型的生育力保留或保留技术，则将包括研究。动物研究,非英语学习,社论,和准则将被排除在审查之外。从纳入的研究来看，数据将通过使用叙述方法进行提取和合成，并在表格中进行汇总。主要结果将是成功接受生育力保存技术的患者数量。次要结果将包括检索到的卵母细胞的数量，冷冻保存的卵母细胞或胚胎的数量，临床妊娠,和活产。纳入研究的质量将通过使用国家心脏进行评估，肺，和血液研究所的偏见风险工具，用于任何类型的研究。
结果：系统综述预计将于2023年底完成，结果将发表在同行评审的期刊上并在PROSPERO上。
结论：拟议的系统综述将总结可用于中枢神经系统癌症患者的生育力保护技术。鉴于癌症生存率的提高，教育病人生育保存技术变得越来越重要。这种系统审查可能存在一些局限性。当前的文献可能由于数量不足而质量低下，访问数据集可能会有困难。然而,我们希望,系统评价的结果提供了一个证据基础,以帮助告知中枢神经系统癌症患者转诊以保留生育力治疗.
背景：PROSPEROCRD42022352810;https://tinyurl.com/69xd9add。
■PRR1-10.2196/44825。
目的：拟议的系统评价的主要目的是评估中枢神经系统癌症患者使用生育力保护技术的最佳证据。它还旨在评估与成功和并发症相关的结果。
方法：本方案遵循PRISMA-P（系统评价和Meta分析方案的首选报告项目）。将系统地搜索电子数据库，以确定符合我们资格标准的研究。如果他们报告任何年龄的男性患者和年龄<35岁的女性患者中至少一种类型的生育力保留或保留技术，则将包括研究。动物研究,非英语学习,社论,和准则将被排除在审查之外。从纳入的研究来看，数据将通过使用叙述方法进行提取和合成，并在表格中进行汇总。主要结果将是成功接受生育力保存技术的患者数量。次要结果将包括检索到的卵母细胞的数量，冷冻保存的卵母细胞或胚胎的数量，临床妊娠,和活产。纳入研究的质量将通过使用国家心脏进行评估，肺，和血液研究所的偏见风险工具，用于任何类型的研究。
结果：系统综述预计将于2023年底完成，结果将发表在同行评审的期刊上并在PROSPERO上。
结论：拟议的系统综述将总结可用于中枢神经系统癌症患者的生育力保护技术。鉴于癌症生存率的提高，教育病人生育保存技术变得越来越重要。这种系统审查可能存在一些局限性。当前的文献可能由于数量不足而质量低下，访问数据集可能会有困难。然而,我们希望,系统评价的结果提供了一个证据基础,以帮助告知中枢神经系统癌症患者转诊以保留生育力治疗.
背景：PROSPEROCRD42022352810;https://tinyurl.com/69xd9add。
■PRR1-10.2196/44825。
